The efficacy of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning depends on the balance between the desirable antineoplastic effects of donor cells weighed against the undesirable morbidity of graft-versus-host disease (GVHD). Development of serious acute or chronic GVHD was analyzed retrospectively in 171 consecutive patients, who had related or unrelated nonmyeloablative HCT for hematologic malignancies. GVHD was defined as serious when it resulted in (1) death, (2) disability, (3) three or more major infections in 1 year, (4) prolonged hospitalization or (5) suicide or hospitalization for suicidal ideation. According to this definition, 43 of 171 (25%) patients developed serious GVHD with a median follow-up of 30 (range, 12-65) months. The incidence of serious GVHD was similar after related and unrelated HCT. Among the 43 patients with serious GVHD, 20 had grade III-IV acute GVHD, and 30 had extensive chronic GVHD. Among the 171 patients, seven had grade III acute GVHD and 84 had extensive chronic GVHD that did not meet criteria for serious GVHD. Assessment of serious GVHD provides additional useful information to acute GVHD grades and classification of limited and extensive chronic GVHD in describing the overall risk and impact complications caused by donor cells.
The use of nonmyeloablative conditioning regimens has made it feasible to offer hematopoietic cell transplantation (HCT) as a potentially curative treatment for patients with hematologic malignancies who would otherwise be excluded because of age or impaired organ function. With this treatment, immune effects mediated by donor T cells represent the primary mechanism for eradication of malignant cells in the recipient. [1] [2] [3] [4] [5] [6] The overall efficacy of this approach depends on the balance between the desirable antineoplastic effects mediated by donor T cells, weighed against the undesirable morbidity of graft-versus-host disease (GVHD). We have recently reported that the incidence rates of steroid treatment were 64 and 73% for acute and chronic GVHD, respectively, after HCT with the use of nonmyeloablative conditioning regimens. 7 These figures compared to 85 and 71% for acute and chronic GVHD, respectively, after myeloablative HCT. In this study, we also observed that manifestations typical of acute GVHD began after day 100 in some recipients of nonmyeloablative HCT. 7 Although previous studies have identified risk factors for acute and chronic GVHD after myeloablative HCT, [8] [9] [10] [11] [12] [13] [14] [15] analysis of serious consequences of GVHD have not been reported after either myeloablative or nonmyeloablative HCT. The present study focused on serious consequences of either acute or chronic GVHD, using pre-specified criteria to identify fatal or disabling outcomes related to GVHD after nonmyelablative HCT. In this retrospective study, we analyzed results from a series of 171 consecutive patients with hematologic malignancies who had HCT from either related or unrelated donors after a nonmyeloablative conditioning regimen. As immune effects mediated by donor cells represent the primary mechanism for eliminating malignant cells after nonmyeloablative HCT, our analysis focused on acute or chronic GVHD that caused death, severe disability, major infections, prolonged hospitalization, suicide or hospitalization for suicidal ideation.
Patients and methods

Definition of serious GVHD
For this study, serious acute or chronic GVHD was defined as (1) death related to GVHD or its treatment; (2) severe disability because of GVHD or its treatment; (3) three or more major infections in a single year during persistent GVHD; (4) hospitalization for 460 days in a single year because of GVHD or (5) suicide or hospitalization for suicidal ideation because of GVHD or its treatment (Table 1) .
Selection of patients
The study cohort included all of the 171 patients who had nonmyeloablative conditioning after HCT at our center between January 1998 and May 2002. Related or unrelated donors and recipients were serologically matched for HLA-A, B and C and allele-matched for HLA-DRB1 and DQB1. Details regarding patient age, donor type, donor-recipient gender, diagnosis, stage of disease, hematopoietic stem cells source, preparative regimen, prior myeloablative hematopoietic transplant and number of cells infused are listed in Table 2 . Patients were 5-73 (median, 55) years of age. In most patients (78%), the underlying hematologic malignancies were not in remission at the time of HCT. In total, 27% of patients had persistent malignancy despite previous treatment with a myeloablative conditioning regimen and HCT. Patients and donors signed forms approved by the Institutional Review Board documenting informed consent to participate in clinical trials. For all patients, results were analyzed according to data available as of March 2003.
Transplant protocols
The preparative regimen included 2 Gy total body irradiation (TBI) on the day of transplant (day 0) with or without fludarabine (30 mg/m 2 /day on days À4, À3 and À2). The postgrafting immunosuppressive regimen was mycophenolate mofetil (15 mg/kg orally twice daily) starting 4-6 h after HCT on day 0 and cyclosporine (CSP) starting on day À3 (initially at 6.25 mg/kg orally twice daily). The duration of CSP given after related HCT was gradually extended from day 35 to discontinuation at day 180 in patients without GVHD, according to evolving treatment protocols. 1, 7, 16, 17 In unrelated HCT recipients without GVHD, MMF doses were tapered over 56 days starting on day 40, and CSP doses were tapered over 180 days, starting on day 100. In related HCT recipients without GVHD, MMF was discontinued on day 27. Supportive-care has been described previously. 1, 7, 16, 17 Prophylaxis against Pneumocystis carinii (PCP), bacterial, fungal and cytomegalovirus (CMV) infections was used as previously reported. [18] [19] [20] [21] Patients with chronic GVHD requiring systemic immunosuppression received pre-emptive therapy for CMV infection and antibiotic prophylaxis against PCP, H influenzae and S pneumoniae infections. [22] [23] [24] Donor lymphocyte infusions (DLI) were administered to eligible patients who had mixed chimerism or persistent or progressive malignancy without manifestations of GVHD. 25 Evaluation of chimerism in aspirated marrow samples and in blood T cells and granulocytes was assessed periodically after the transplant. 26 Diagnosis and treatment of GVHD Diagnosis and grading of acute [27] [28] [29] and chronic 14, 15, 30, 31 GVHD were performed according to established criteria. Treatment decisions were based on the attending physician's assessment of the severity of acute GVHD, and the usual initial treatment was prednisone at 1-2 mg/kg per day for 14 days followed by tapering of steroid doses. In addition, the administration of CSP or mycophenolate mofetil was usually resumed at full doses. Treatment for extensive chronic GVHD was prednisone at 1 mg/kg/day with twice daily CSP followed by a taper to alternate-day corticosteroids at 1 mg/kg. 32, 33 Several strategies were used to treat steroid-refractory chronic GVHD, 14, 33 including administration of mycophenolate mofetil, [34] [35] [36] tacrolimus, 37 sirolimus, 38 thalidomide, 39, 40 psoralen and UVA 41 and extracorporeal photopheresis. 42, 43 Medications administered for control of chronic GVHD were continued for at least 9 months unless changes in therapy were clinically indicated.
Statistics
The cumulative incidence of serious GVHD as defined above was estimated according to previously described methods. 44 Proportions were evaluated according to the w 2 test, and the numbers of treatment cycles for acute and chronic GVHD were evaluated by the Wilcoxon rank sum test.
Results
In the study cohort of 171 patients with a median follow-up of 30 (range, 12-65) months, 43 (25%) developed serious GVHD. The onset of GVHD occurred at a median of 6.0 (range, 1.9-35.4) months after transplant. The cumulative incidence of serious GVHD was 3% at 100 days after the transplant, 12% at 6 months, 20% at 1 year and 26% at 2 years ( Figure 1) . DLI was given to 12 patients because of progression or recurrent malignancies. Three of the 12 (25%) developed serious GVHD at 5.5, 5.2 and 5.3 months after HCT (at 3.1, 3.6 and 2.6 months after DLI).
Characteristics of patients according to the presence or absence of serious GVHD after nonmyeloablative HCT are shown in Table 2 . Of 171 patients, 16 did not develop either acute or chronic GVHD. Table 3 summarizes the overall incidence of acute and chronic GVHD for this study cohort categorized according to the presence or absence of serious GVHD. Among the 43 patients with serious GVHD,20 had grade III-IV acute GVHD, and 30 had extensive chronic GVHD (Table 3) . Among the 171 patients in the study, seven had grade III-IV acute GVHD and 84 had extensive chronic GVHD that did not meet criteria for serious GVHD. Skin and gastrointestinal tract were the organs most frequently affected in patients with serious GVHD (Table 4) . As expected, the numbers of successive systemic treatments given to control GVHD were higher among patients with serious GVHD than among those with GVHD that was not serious (Po0.001) ( Table 5) .
Death related to GVHD was the most frequent reason for the classification as serious GVHD (Table 4 ). Major causes of death (n ¼ 38) among patients with serious GVHD were infections with persistent GVHD (n ¼ 25), organ failure including liver failure (n ¼ 2), gastrointestinal hemorrhages (n ¼ 2) and bronchiolitis obliterans with organizing pneumonia (n ¼ 2), corticosteroid-induced Figure 1 Cumulative incidence of serious graft-versus-host disease after nonmyeloablative hematopoietic stem cell transplantation for treatment of hematologic malignancies. The figure displays the onset of serious GVHD according to the day on which any consequences of GVHD first fulfilled any of the criteria in the definition.
Table 3
Acute and chronic GVHD after nonmyeloablative hematopoietic transplant and according to the presence or absence of serious GVHD necrotizing pancreatitis (n ¼ 1) and infections with GVHD and persistent or recurrent malignancy (n ¼ 6). A total of 13 patients had complications other than death as causes for categorization as serious GVHD (Table 4) . Of 128 patients, 44 without serious GVHD died as a consequence of persistent or recurrent malignancy (n ¼ 23), infections without GVHD (n ¼ 12), pulmonary or cerebral hemorrhage (n ¼ 2), secondary malignancy (n ¼ 2), idiopathic interstitial pneumonia (n ¼ 1) or pancreatitis (n ¼ 1). In one patient, the cause of death could not be identified.
Discussion
Nonmyeloablative conditioning for allogeneic HCT has been developed to decrease regimen-related toxicities while preserving the antitumor effects of donor-derived cells in patients who otherwise are ineligible for conventional myeloablative conditioning transplants due to increased age or comorbidities. [1] [2] [3] [4] [5] [6] GVHD-related morbidity is an extremely important outcome after allogeneic HCT, but current criteria for assessing GVHD-associated morbidity can be difficult to apply among patients who have received nonmyeloablative conditioning. For example, steroid treatment for acute GVHD begins beyond 3 months from HCT in a considerable proportion of patients who have received nonmyeloablative conditioning, thereby obviating the traditional day-100 cutoff criteria for separation of acute from chronic GVHD. 7 In addition, manifestations of acute and chronic GVHD can be present simultaneously in patients treated with DLI. 45 These considerations indicate the need for improved criteria that would be applicable for assessment of any type of GVHD, regardless of the onset interval after transplant.
Owing to difficulty in assessing the severity of acute and chronic GVHD in patients who have received nonmyeloablative conditioning, 7 we elected to focus on disability, death or threat to life as major consequences of GVHD, using prespecified criteria in this patient population. The definition of serious GVHD proposed in this study followed the pattern set by regulatory definition of serious adverse events. Both definitions describe the consequences of an adverse event rather than its severity. Survival cannot be used to validate the definition of serious GVHD, and the occurrence of serious GVHD cannot be used as a prognostic indicator of survival, because death caused by GVHD represents a component in the definition of serious GVHD.
Results in Table 3 illustrate the shortcomings of using separate analyses of acute and chronic GVHD to understand the overall medical impact of immune reactions mediated by donor cells after allogeneic HCT. According to the proposed definition, 25% of patients in the overall study population had serious GVHD, but only 16% had grades III-IV acute GVHD, because some of the patients with grades 0-II acute GVHD had serious chronic GVHD. Moreover, not all patients with grade III acute GVHD had serious GVHD. The current classification system does not account for the considerable variation in morbidity among patients with extensive chronic GVHD. In our study, 114 of the 147 patients who survived for more than 100 days developed extensive chronic GVHD (76%), but according to the proposed definition, only 30 had serious GVHD (20%). In addition, 14% of the patients died before they could develop chronic GVHD. Finally, some patients with grades III-IV acute GVHD also have severe morbidity or death caused by chronic GVHD. For this reason, the overall impact of GVHD cannot be estimated simply by adding the number of patients with grades III-IV acute GVHD to the number with severe morbidity or death caused by chronic GVHD.
Future studies will be needed to assess serious GVHD after myeloablative conditioning regimens. However, direct comparisons of serious GVHD after nonmyeloablative vs myeloablative HCT in retrospective studies may be difficult, because of striking differences of the patient populations. For example, recipients of nonmyeloablative Table 4 Characteristics of serious GVHD HCT are older than recipients of myeloablative HCT and many have had a prior myeloablative transplant. Nonmyeloablative HCT recipients often have comorbidities that have excluded them from conventional myeloablative HCT, and most received G-CSF mobilized donor blood cells. [1] [2] [3] [4] [5] [6] [7] Increasing patient age and advanced malignancies are risk factors for the development of GVHD after myeloablative HCT, and the use of G-CSF-mobilized blood cells has been associated with a longer duration of GVHD as compared to bone marrow as the source of HCT. [46] [47] [48] In addition, differences in regimen-related tissue damage and postgrafting immunosuppression might also translate into different patterns of GVHD with the two types of transplant. Nonetheless, an earlier retrospective comparison showed a higher incidence of acute GVHD and steroid usage among patients after myeloablative compared to nonmyeloablative conditioning. 7 We consider the definition of serious GVHD to be provisional, and we expect that the definition will benefit from further refinement in future studies. For example, the definition should include GVHD-related severe ocular symptoms sufficient to impair normal activity of daily living. We did not include severe eye problems caused by GVHD in the present study because this information was not recorded in all patients. To some extent, the exact numbers and types of infection included in the definition of serious GVHD in this study are arbitrary, and details of the definition may be subject to debate. Nonetheless, the infections included in the definition have considerable clinical relevance and reflect impaired mucosal barrier function and immunodeficiency associated with GVHD.
We propose that similar analysis of serious GVHD could provide highly useful descriptive information from retrospective studies of outcomes after transplantation with either nonmyeloablative or myeloablative conditioning regimens. Similarly defined serious GVHD could also be used as a highly meaningful descriptive end point in prospective studies. Lastly, patients should be informed about the risk of serious GVHD when considering allogeneic HCT as a treatment option, since separate estimates of the incidence of grades III-IV GVHD and severe chronic GVHD do not adequately describe the overall risk and impact of medical complications caused by donor cells.
